Longevity biology has moved from speculative to empirical faster than most scientific fields. We now have identified mechanisms — mTOR, sirtuins, senescent cells, NAD+ metabolism, mitochondrial function — that are legitimately druggable and being actively investigated in clinical trials. Here is an evidence-graded overview of the major categories and where peptides fit. This overview specifically addresses longevity stacks, and related research is indexed on PubMed.
NAD+ Precursors: NMN and NR
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy metabolism, DNA repair (via PARP enzymes), and sirtuin activation. NAD+ levels decline with age in humans and animal models — this is well-established. Whether supplementing with precursors (NMN or NR) reverses aging-related decline is a more contested question.
Animal Model Evidence
Robust. Multiple studies in rodents show NMN/NR administration raises NAD+ tissue levels, improves metabolic parameters, extends healthspan in various aging models. Dr. David Sinclair’s lab (Harvard) published extensively on this, including the 2013 Cell paper showing muscle NAD+ restoration reversed some vascular aging markers in aged mice.
Human Evidence
Emerging but modest. A 2022 randomized trial in Nature Aging (n=30, aged adults) showed NMN supplementation raised blood NAD+ levels but did not produce significant changes in metabolic markers. Multiple small RCTs show NAD+ elevation is achievable; downstream functional benefits in humans remain under active investigation. Several large trials are ongoing.
Senolytics: Clearing Senescent Cells
Cellular senescence — cells that stop dividing but don’t die, secreting pro-inflammatory signals (SASP) — accumulates with age and is causally linked to multiple aging phenotypes in animal models. Senolytics are compounds that selectively eliminate these cells.
- Dasatinib + Quercetin: The most-studied senolytic combination. Multiple Mayo Clinic studies in humans, including an open-label trial in idiopathic pulmonary fibrosis (a senescence-driven disease) showing functional improvements. D+Q is entering formal RCTs.
- Fisetin: A flavonoid with senolytic properties in rodent models. Human pharmacokinetic data exists; efficacy trials in progress.
- Navitoclax (ABT-263): BCL-2/BCL-XL inhibitor with strong senolytic activity — but platelet toxicity limits clinical application.
mTOR Inhibition: Rapamycin
Rapamycin (sirolimus) inhibits mTOR complex 1, a nutrient-sensing pathway that when chronically activated accelerates aging-related pathways. It is the only compound that has consistently extended lifespan in multiple mammalian studies, including published mouse studies showing lifespan extension even when started late in life.
Human longevity trials are ongoing (the PEARL trial). Rapamycin is FDA-approved as an immunosuppressant for organ transplant — so there is significant human safety data, though not from longevity use contexts.
Where Peptides Fit
Peptides intersect longevity biology at several points:
- GH axis peptides (Ipamorelin, CJC-1295): GH/IGF-1 axis declines with age (somatopause). Whether restoring GH pulses via secretagogues has longevity-relevant effects is under investigation — the data is mechanistically plausible but outcome data is limited.
- Epithalon (Epitalon): A tetrapeptide studied by the Russian gerontologist Vladimir Khavinson for decades, proposed to extend telomere length and activate telomerase. Animal studies exist; human RCT data is very limited but some observational studies have been published.
- Thymosin Alpha-1: Thymic peptide with immunomodulatory properties — immune function declines (immunosenescence) is a hallmark of aging. Published clinical data from approved use in hepatitis and cancer immunotherapy contexts.
- BPC-157: Anti-inflammatory and tissue-protective properties intersect with senescence biology (SASP is inflammatory). Speculative connection but mechanistically discussed.
The Gold Standard for Longevity Claims: The Interventions Testing Program
When evaluating any longevity intervention’s animal data, it’s worth knowing about the NIA Interventions Testing Program (ITP) — a US National Institute on Aging-funded initiative that independently tests candidate longevity compounds simultaneously across three separate research sites (currently the Jackson Laboratory, University of Michigan, and University of Texas Health Science Center) using genetically heterogeneous mice, specifically to guard against the single-lab, single-strain result inflation that has historically plagued longevity research. Rapamycin’s lifespan-extension effect is among the most robustly ITP-confirmed findings in the field — replicated across sites and mouse cohorts, which is a meaningfully higher evidentiary bar than a single-lab rodent study. Very few of the peptides discussed elsewhere on this page (or on this site generally) have been tested through the ITP; most rely on single-lab, often single-strain rodent data, which is a real and specific evidentiary gap worth flagging whenever a “extends lifespan in animal studies” claim is made without specifying whether ITP-style multi-site replication exists.
Epithalon and Telomerase: A Claim Requiring Extra Scrutiny
Epithalon’s proposed telomerase-activation mechanism deserves a specific note of caution beyond the general limited-human-data point already made. Telomerase activation is mechanistically double-edged: while telomere shortening is associated with cellular aging, telomerase reactivation is also a hallmark of the large majority of human cancers, which reactivate telomerase specifically to enable unlimited cell division. This means any telomerase-activating compound’s safety profile requires unusually careful long-term cancer-risk evaluation — a bar that, per the evidence tiering already noted, Epithalon’s current human data does not yet clear. This isn’t a claim that Epithalon causes cancer; it’s a statement that the same mechanism proposed as its longevity benefit is mechanistically linked to a serious theoretical risk that any responsible evaluation of this compound needs to weigh explicitly, rather than treating telomerase activation as an unambiguously positive property.
Frequently Asked Questions
What makes the ITP’s mouse studies more rigorous than typical single-lab research?
Testing occurs simultaneously across three independent sites using genetically heterogeneous (not inbred single-strain) mice, specifically designed to catch results that don’t replicate outside one lab’s specific conditions — a substantially higher bar than most published rodent longevity studies meet.
Is telomerase activation always beneficial for longevity?
Not straightforwardly — while telomere shortening is linked to cellular aging, telomerase reactivation is also a defining feature of most cancers, making any telomerase-activating compound’s long-term safety profile, particularly regarding cancer risk, an area requiring careful and specific evaluation rather than an assumed benefit.
Has rapamycin’s lifespan-extension effect in mice been independently replicated?
Yes — it’s among the findings most robustly confirmed through the NIA Interventions Testing Program’s multi-site replication design, which is part of why it’s frequently cited as having comparatively strong preclinical support relative to most other longevity compounds discussed in this space.
Evidence Hierarchy for This Space
Strong mechanistic understanding + robust animal data → NMN/NR, senolytics, rapamycin
Early human data → D+Q senolytics, NMN (NAD+ elevation), Thymosin Alpha-1
Animal/preclinical only → most peptides in this context, Epithalon
Theoretical/extrapolated → most peptide-longevity combinations
This is an exciting area of research precisely because the mechanistic understanding is advancing rapidly while human outcome data lags. Educational content only — not medical advice or treatment recommendations.
